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Abstract
Background: Many double-blind clinical trials of transcranial direct current stimulation (tDCS) use stimulus intensities of
2 mA despite the fact that blinding has not been formally validated under these conditions. The aim of this study was to
test the assumption that sham 2 mA tDCS achieves effective blinding.
Methods: A randomised double blind crossover trial. 100 tDCS-naı¨ve healthy volunteers were incorrectly advised that they
there were taking part in a trial of tDCS on word memory. Participants attended for two separate sessions. In each session,
they completed a word memory task, then received active or sham tDCS (order randomised) at 2 mA stimulation intensity
for 20 minutes and then repeated the word memory task. They then judged whether they believed they had received active
stimulation and rated their confidence in that judgement. The blinded assessor noted when red marks were observed at the
electrode sites post-stimulation.
Results: tDCS at 2 mA was not effectively blinded. That is, participants correctly judged the stimulation condition greater
than would be expected to by chance at both the first session (kappa level of agreement (k) 0.28, 95% confidence interval
(CI) 0.09 to 0.47 p = 0.005) and the second session (k= 0.77, 95%CI 0.64 to 0.90), p =,0.001) indicating inadequate
participant blinding. Redness at the reference electrode site was noticeable following active stimulation more than sham
stimulation (session one, k= 0.512, 95%CI 0.363 to 0.66, p,0.001; session two, k= 0.677, 95%CI 0.534 to 0.82) indicating
inadequate assessor blinding.
Conclusions: Our results suggest that blinding in studies using tDCS at intensities of 2 mA is inadequate. Positive results
from such studies should be interpreted with caution.
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Introduction
Transcranial direct current stimulation (tDCS) is a non-invasive
method of electrical stimulation of the cortex and has been shown
to modulate brain activity specific to the site and parameters of
stimulation [1]. tDCS research has ranged from the investigation
of its physiological effects on brain activity and function [1], to a
range of clinical applications, most notably chronic pain [2–5],
depression [6] and stroke [7].
Clinical evaluation of tDCS is considered superior to that of
other non-invasive brain stimulation methods because the
stimulation condition can be concealed through the use of a sham
condition [8]. Sham tDCS involves an identical process to active
stimulation but, without the participant’s knowledge, the stimu-
lator is switched off after around 30 seconds. Gandiga, et al. [9]
reviewed the results of two crossover studies involving participants
undergoing tDCS at 1 mA intensity or sham and found that the
stimulation condition could not be distinguished by participants or
blinded investigators. Ambrus et al. [10] highlighted the benefit of
naivety by showing that, although even experienced participants
could be effectively blinded using 1 mA or sham, when the
participant was an experienced tDCS investigator, blinding was
less effective. That is, even with low intensity tDCS, naivety is
important for effective blinding from sham.
Many clinical trials involving tDCS use 2 mA stimulation and
presume effective blinding [for example 2,3]. Largely on the basis
of these trials, tDCS is considered a very promising therapeutic
tool. tDCS at 2 mA is associated with more sensory effects than
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tDCS at 1 mA [11], which clearly casts doubt over assumption of
effective blinding. Almost all trials of tDCS for chronic pain
identified in a recent Cochrane review [12] used stimulation
intensities of 2 mA. Only one parallel study [5] reported
difficulties with participant blinding and even then did not
elaborate on those difficulties. Conversely two parallel trials of
tDCS for depression reported that effective treatment masking was
maintained [13,14]. Our group recently undertook a clinical
crossover study [15] of tDCS at 2 mA for chronic back pain and
found that participants may have been able to distinguish between
the active stimulation and sham condition and a crossover study of
tDCS for food cravings has similarly reported inadequate blinding
[16].The use of a crossover design might be particularly
problematic because exposure of participants to both active
stimulation and sham increases the likelihood that they will
distinguish one as more credible than the other. In addition to
concerns over participant blinding, blinded assessors may also be
able to distinguish between conditions because of skin redness that
is observable at the electrode sites, primarily under the reference
electrode, after active but not sham stimulation [11]. Given the
growing endorsement of 2 mA tDCS as a therapeutic tool, it is
remarkable that the assumption that such studies are effectively
blinded has not been formally tested. The need for such testing
was recently highlighted in a review of challenges for tDCS
research [11]. We aimed to determine how well 2 mA tDCS can
be blinded against a sham stimulation condition. Our primary
research questions were ‘‘At stimulation intensities of 2 mA, do
people correctly judge the true stimulation condition more than
would be expected by chance and is this judgement influenced by
previous exposure to sham or real stimulation?’’ and ‘‘At
stimulation intensities of 2 mA, is skin redness at the visible
electrode site more visible to the blinded assessor following active
stimulation than it is following sham?’’.
Methods
This study had full approval from the School of Health Sciences
and Social Care Research Ethics Committee, Brunel University
and conformed to the Helsinki declaration. All participants gave
written informed consent. This study used a double-blind
randomised crossover design.
Participants
Healthy individuals aged over 18, were recruited from staff and
students at Brunel University, and their family and friends.
Participants must have had no prior experience of tDCS
stimulation. Exclusion criteria were prior/existing history of
neurological disease, psychiatric disorder, dyslexia, diabetes,
epilepsy, head injury, musculoskeletal or neurological injury to
the limb, dermatological condition affecting the scalp, poor
understanding of written English or any other communication
impairment.
Recruitment
To establish conditions that best reflected what might occur in
clinical trials of tDCS, participants were misdirected regarding the
true research question. We misinformed participants that the study
aimed to investigate the potential effects of tDCS on a word
memory recognition task. The purpose of this deception was to
reduce the likelihood that participants would afford more attention
to distinguishing between the active stimulation and sham
conditions than they might during a clinical trial of tDCS.
However in the event that blinding was found to be adequate we
planned to perform a formal analysis of the effect of tDCS on
performance of this task. Although participants were informed that
the study would involve both real and sham conditions, they were
not informed about the true research question. We made this
deception clear in our application for ethical approval and
received approval to proceed in this way.
Outcomes
The primary outcomes were:
1. The participant’s YES/NO answer to the question ‘‘Do you
feel that you have just received the real brain stimulation?’’
2. A 10 cm Visual Analogue Scale (VAS) of the participant’s
confidence in that judgement, worded as follows ‘‘Please place
a mark on the line below that best represents your level of
confidence in that judgement.’’ The left anchor was labelled
‘‘not confident at all’’ and the right anchor was labelled
‘‘completely confident’’.
To answer the second research question the assessor docu-
mented every occasion the participant had noticeable skin redness
at the visible electrode site(s) following stimulation. This was
documented as a simple YES/NO response. No formal threshold
of skin redness was used as we wished to simply note when the
assessor might be aware of noticeable redness in a clinical trial.
We did not question participants further regarding their
perceptions or sensations during or after the stimulation to avoid
making this the focus of their attention during the study.
Procedure
All eligible participants were randomised to an order of
stimulation (active followed by sham, or vice versa). The
randomisation schedule for all participants was established prior
to recruitment by an independent administrator using a computer
generated random numbers sequence (http://www.randomizer.
org/). A randomly generated list of numbers 1 and 2 was
generated (1 = active stimulation first, 2 = sham stimulation first)
and each of these numbers was sealed in an opaque envelope with
a corresponding participant number. The corresponding envelope
was accessed for each consecutive participant on the day of the
first stimulation session by the sole unblinded researcher who
delivered the stimulation (JC) and who had no involvement in the
recruitment or assessment process. Neither the participant nor the
assessor (NO’C) were informed of the stimulation order and the
randomisation code was maintained until all participants had
completed the study.
Participants visited the laboratory twice with a minimum 2 week
washout period between visits. At each visit, participants
completed the word memory task, and then received their
stimulation (active or sham). Participants were then asked to
report any adverse events and this was followed by a repeat of the
word memory task. Participants then completed the form
concerning their judgement of the stimulation condition. Although
it was the primary research question, this form was undertaken at
the end of the visit to appear secondary. The question, and the
participant’s response, was discussed in no more detail than that
required for successful completion.
tDCS Stimulation
tDCS was delivered using a battery driven CX-6650 ramp
controlled DC stimulator (Rolf Schneider Electronics, Germany).
Current was delivered by electrodes encased in sponge pads
(35 cm2) soaked with 0.1% (140 mMol) saline solution. The
machine was kept behind the participant and was out of the view
of both the participant and the blind assessor for the entire
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stimulation period. For both the active and sham conditions, the
anode was placed over the left motor cortex of the subject and the
cathode was placed over the contralateral supraorbital region.
Electrodes were secured using soft elastic straps. The location of
the motor cortex was estimated using the international 10–20
EEG system, with the centre of the electrode pad located 1 cm
anterior and 4 cm lateral to the vertex.
In the active stimulation condition, a constant current of 2 mA
intensity (current density 0.057 mA/cm2) was applied for 20
minutes, with a 5 second ramping phase at the beginning and end
of stimulation. In the sham stimulation condition, the machine was
activated using identical parameters but was switched off without
the participant’s knowledge after 30 seconds. The researcher who
applied the stimulation recorded the voltage levels 30 seconds after
the onset of stimulation.
The Memory Task
In order to maintain the impression that the study aimed to test
the effects of tDCS on memory we used a standard word
recognition test, which was performed by the participants on a
laptop computer using E-Prime software (Psychology Software
Tools, Sharpsburg USA).
Data Analysis
For the primary analysis, the data from each session were
analysed separately to answer the research question for parallel
and crossover study designs. Analyses were performed using IBM
SPSS version 18 statistical software.
We used the Kappa measure of agreement (k) to test whether
participants successfully judged the stimulation condition more
than would be expected by chance and to test whether the assessor
noticed a visible redness following stimulation on the skin under
the electrode sites more commonly after active stimulation than
they did after sham. This was in almost all cases noticed under the
reference electrode. Cut-offs for characterizing the level of
agreement were ,0.2 poor, 0.21–0.4 Fair, 0.41–0.6 Moderate,
0.61–0.8 Good, 0.81–1 very good [17].
We investigated differences in participants’ confidence about
their judgements with the following factors: stimulation condition
(active/sham), participant’s judgements regarding whether they
had received active stimulation (yes/no) and session number (first
or second) using the appropriate non-parametric test. We accepted
statistical significance for all tests at a,0.05.
Results
We recruited 100 participants (75 female). The mean (SD) age
was 24 (8.3), range 18–62. Fifty-four participants were randomly
allocated to receive active stimulation followed by sham. Ninety-
nine participants completed the first stimulation session in full.
One female participant withdrew from the study in the first session
because they could not tolerate the stimulation. Three participants
(2 female) did not attend for a second session: two stated that they
were too busy to participate further and one did not respond to
correspondence. We obtained complete data from 96 participants.
Methodological Checks
Participants’ confidence ratings and the initial stimulation
voltage were not normally distributed.
Participant Blinding
Table 1 presents the data for participants’ judgements of the
stimulation condition.
Session one. 72% of participants who received active
stimulation, and 56% of participants who received the sham,
correctly judged the stimulation condition. Overall, 65% of
participants correctly judged the stimulation condition they
received which represents a ‘‘fair’’ level of agreement (k= 0.28,
95% confidence interval (CI) 0.09 to 0.47 p = 0.005).
Session two. 89% of participants who received active
stimulation and 88% of participants who received sham judged
correctly, which represents a ‘‘good’’ level of agreement (k= 0.77,
95%CI 0.64 to 0.90), p,0.001).
Participant Confidence
Participants’ confidence in their judgement of the stimulation
condition was significantly higher in the second stimulation session
(median (IQR) 6.55 (1.85 to 7.3) than it was the first stimulation
session (5.6 (3.77 to 8.48)) (Wilcoxon signed rank test, p,0.001).
Confidence was higher where participants judged they received
active stimulation in the first session (median (IQR) judged ‘‘Yes’’
6.4 (2.3 to 7.9), judged ‘‘No’’ 3.050 (1.65 to 6.65), Mann Whitney
U test p = 0.028) but not in the second stimulation session (judged
‘‘Yes’’ 7 (5.25 to 8.8), judged ‘‘No’’ 6 (2.7 to 8), p = 0.173).
Assessor Blinding
Table 2 presents the frequency that the assessor noticed skin
redness at the visible electrode site(s) under both stimulation
conditions. The assessor noticed skin redness at the electrode site(s)
following stimulation significantly more often following active
stimulation than following sham stimulation in both the first
session, with a ‘‘moderate’’ level of agreement (k= 0.512, 95%CI
0.363 to 0.66, p,0.001), and in the second session (k= 0.677,
95%CI 0.534 to 0.82, p,0.001). Skin redness was noted after 60%
of active stimulation sessions and after 1% of sham stimulation
sessions.
Stimulation Voltage
The median voltage (IQR) at the start of stimulation was 9.2
(7.7 to 11.8). To test whether the initial voltage may have
influenced our results the initial stimulation voltage was compared
between stimulation conditions (active versus sham) and between
participants’ judgements (judged ‘‘yes’’ or ‘‘no’’ to whether they
thought they had received active stimulation). No significant
difference in voltage was observed for either comparison (Kruskal-
Wallace test, by stimulation condition p = 0.693, by participants’
judgement p = 0.377.).
Table 1. Participant’s judgements of the stimulation
condition, for each stimulation condition and session.
Participants Judgements Stimulation condition Totals
Active
Stimulation
Sham
Stimulation
Session 1 Judged ‘‘yes’’ 39 20 59
Judged ‘‘no’’ 15 25 40
Totals 54 45 99
Session 2 Judged ‘‘yes’’ 39 6 45
Judged ‘‘no’’ 5 46 51
Totals 44 52 96
(‘‘Yes’’ reflects a judgement of active stimulation, ‘‘No’’ reflects a judgement of
sham stimulation.).
doi:10.1371/journal.pone.0047514.t001
Trials of 2mA tDCS Are Not Adequately Blinded
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e47514
Missing Data/sensitivity Analysis
To test whether the missing data may have significantly
influenced our findings we reanalysed the data on participants’
judgements, substituting all correct responses for the missing
values, and then substituting all incorrect responses for the missing
values. We did this separately for each stimulation session. The
results remained significant, for both the first and second sessions,
with both approaches (all incorrect session 1, k= 0.268, 95% CI
0.088 to 0.456; session 2 k= 0.699 95%CI 0.559 to 0.839. all
correct session 1 k= 0.29 (95%CI 0.102 to 0.47; session 2
k= 0.779, 95%CI 0.659 to 0.902).
Adverse Events
There were no serious adverse events. When the first session was
active stimulation, four participants reported an itch that was
perceptible throughout the duration of stimulation. One of these
participants reported a strong tingling that persisted for the first 2
minutes of stimulation. One participant reported a strong tingling
sensation throughout the stimulation and one reported feeling
dizzy and drowsy during the stimulation. When the first session
was sham, one participant reported mild dizziness during and
immediately after, one was unable to tolerate stimulation in the
initial 30 second ‘‘on’’ phase due to dizziness and withdrew from
the study, although these symptoms had resolved five minutes post
stimulation. In the second stimulation session, one participant
reported mild dizziness during sham stimulation and one reported
feeling drowsy during and immediately after active stimulation.
Memory Task Data
The memory task was used primarily to distract participants
from the true aim of the study. Given that the results have
demonstrated that blinding of participants is imperfect it would be
problematic to confidently attribute any observed effect on the
memory task to the effects of stimulation, or indeed to the placebo
effect. As such we did not analyse this data further.
Discussion
Our results demonstrate that tDCS at 2 mA is not associated
with effective blinding when compared with the commonly used
sham using this electrode montage and stimulation procedure. For
a proportion of tDCS naı¨ve participants, blinding is maintained,
but the probability of a participant correctly identifying the
stimulation condition is greater than would be expected by chance.
Given the high agreement in the second session, the threat to
participant blinding appears substantially worse for crossover
trials. Participants were more confident in their judgement where
they judged that they were receiving active stimulation after the
first session though this difference diminished by the second
stimulation session.
It is highly likely that the sensory effects of active stimulation
were responsible for compromising participant blinding. Famil-
iarity with the experience of stimulation and the ability to compare
between sessions amplified this issue after the second stimulation
session. Reports of persistent itch or tingling during stimulation in
response to the adverse events question are suggestive of this. Most
participants probably would not consider these sensations to be
adverse effects and so only a minority reported them. Assessor
blinding was also compromised in a substantial proportion (60%)
of active stimulation in both sessions and this represents an
important potential source of bias, regardless of study design, in
studies where outcomes are assessed in the immediate post
stimulation period.
The current finding has substantial implications for much of the
existing literature relating to tDCS. For example, 2 mA intensity
and similar electrode montages have been used in almost all trials
of tDCS for chronic pain [11], the majority of sham controlled
tDCS trials for depression, [6,13,14] and all trials of tDCS for
reducing cravings [16,18–20]. All of these studies have reported
superior efficacy of active stimulation over sham and while some
[13,14] report adequate participant blinding, the issue of assessor
blinding was not assessed. While we cannot predict the degree of
influence that inadequate blinding may have had in these studies,
non-specific effects of interventions are known to be important in
such clinical conditions [21,22]. Further, there is evidence that
incomplete blinding leads to exaggerated effects in clinical studies
with subjective outcomes [23], and that placebo effects are larger
with physical placebo interventions [22]. Thus, we contend that
clinical studies that have used 2 mA tDCS should be interpreted
with renewed caution. This point is emphasised by the recognised
phenomenon that trials of new clinical interventions are often
associated with small study effects and a publication bias that
influence the evidence base, with a propensity for negative studies
to not reach full publication [24,25].
How might blinding of tDCS at this intensity be improved?
Assessor blinding might be ensured by having the participant wear
headgear that conceals the area under the electrodes. It is possible
that longer ramping times may improve participant blinding but
this may not be sufficient where participants are aware of
sensations throughout the stimulation period. McFadden et al.
[26] demonstrated that the pre-application of topical anaesthetics
to electrode sites substantially reduced (but did not abolish) the
sensations associated with stimulation, although the same process
would be difficult at more posterior locations in participants with
hair. Any modified sham protocol will require rigorous testing to
ensure adequate blinding.
An alternative approach may be to reduce stimulation intensity.
Indeed, it is not clear that higher stimulation intensities are
necessary in clinical studies [11]. Effects on cortical excitability
have been clearly demonstrated at intensities of 1 mA [1] and
there is evidence to suggest that successful participant blinding is
achievable under these conditions [9,10]. Using intensities of
1 mA in future research may represent a more methodologically
sound option, although it is plausible that reducing the intensity
may reduce potential efficacy. Future studies of tDCS may benefit
from other methods to optimise blinding, for example de facto
masking [27], in which the treatment is not blinded but both
treatments are presented as the active one. De facto masking might
be more problematic if a non-stimulation sham is used that carries
less credibility with participants but would seem very possible if the
‘‘sham’’ condition is active tDCS over a distinct brain area that is
not hypothesized to elicit specific treatment effects.
Table 2. Assessors judgements of skin redness at the
electrode site, for each stimulation condition.
Participants
Judgements Stimulation condition Totals
Active
Stimulation
Sham
Stimulation
Redness noticeable 59 1 60
No redness noticable 39 95 134
Totals 98 96 194
doi:10.1371/journal.pone.0047514.t002
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That we found inadequate blinding using a therapy widely held
as blindable [8] raises the possibility that clinical trials of other
therapies are vulnerable to similar problems. One obvious
example is in trials of TENS, in which the sham condition often
involves a deactivated TENS unit and as such there will be distinct
differences in the experience of stimulation. It is important to also
acknowledge that inadequate blinding is not the only threat to the
validity of clinical trials and continued attention should be paid in
the design of trials to ensuring rigour in the selection and
allocation process of future trials [28].
Our study has some limitations. We did not investigate the
perceptual correlates of stimulation in any detail. We took this
decision so as to minimise the risk that participants would over-
scrutinize the experience of tDCS, which we felt would not
accurately reflect the conditions of the average clinical trial. As
such we cannot tell with confidence which factors most impacted
on blinding. The VAS scale that we used to measure participants’
confidence in their judgements has not been specifically validated
for that task and may have lacked sensitivity and validity, although
this would not confound our results so much as reduce our power
to detect non-blinding. The predominance of female participants
might plausibly have affected our results. There is some evidence
that differences exist between males and females, in pain threshold
and pain evoked by a standard noxious stimulus, but the nature of
the difference depends upon the type of stimulus and the context
in which it is tested (see [29]for a review). There is also some
debate as to whether pain thresholds vary in females according to
stage of their menstrual cycle [30–32]. However, randomisation of
the order of stimulation should mitigate any potential impact of
these issues on our data. Finally the persistence of noticeable skin
redness that persists beyond the immediate post-stimulation period
represents a further risk to participant blinding and suggests that
our results may underestimate the scale of the problem.
In conclusion, contrary to the assumption of blinding, which
underpins the growing support of tDCS for clinical conditions, our
data show that both participant and assessor blinding is
compromised at 2 mA intensity when using this electrode montage
and stimulation procedure. The findings have important implica-
tions for the interpretation of studies which have utilised this
approach and for the design of future tDCS studies.
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